EBITDA Margin % is calculated as EBITDA divided by its Revenue. Natera's EBITDA for the
three
months ended in Dec. 2023 was $-68 Mil. Natera's Revenue for the
three
months ended in Dec. 2023 was $311 Mil. Therefore, Natera's EBITDA margin for the quarter that ended in Dec. 2023 was -21.79%.
Natera EBITDA Margin % Historical Data
The historical data trend for Natera's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Natera's EBITDA Margin %
For the Diagnostics & Research subindustry, Natera's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Natera's EBITDA Margin % falls into.
Natera EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Natera's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (NAS:NTRA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Natera EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Natera's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 